Acelyrin, Inc. , a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
Acelyrin stock last closed at $2.47, up 0.82% from the previous day, and has decreased 40.91% in one year. It has overperformed other stocks in the Biotechnology industry by 0.36 percentage points. Acelyrin stock is currently +33.88% from its 52-week low of $1.85, and -65.93% from its 52-week high of $7.25.
At the moment, there are 100.71M SLRN shares outstanding. The market cap of SLRN is $248.75M. In the last 24 hours, 366,479 SLRN shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy SLRN stock.
We believe that eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've chosen the best brokerage, the next step is to fill out some personal info so you are able to invest in SLRN today.
Now that you've finished signing up on the best stock trading app for beginners, you can securely and quickly fund your account:
Watch the video below to see the process of transferring funds into your new brokerage account.
After you have figured out the best place to buy Acelyrin stock, it's important to research their stock before you invest, so you actually understand the risk as well as the upside.
WallStreetZen was created to help average investors do better fundamental analysis quickly.
You can see all of the due diligence checks on SLRN's stock page.
You can use many financial metrics, analyses, models, and charts to gauge SLRN's fair value.
Using relative valuations metrics:
You can access more valuation analysis on SLRN's stock here.
Out of 3 Equities analysts who give recommendations on SLRN, the consensus analyst rating on SLRN is a Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Acelyrin stock forecast page.
Over the last year, executives and large shareholders at SLRN have sold more shares than they have bought.
Mina Kim, Chief Executive Officer of SLRN, was the latest SLRN insider to sell. They sold $49,353.58 worth of SLRN stock on Mar 17, 2025.
Learn more about who owns SLRN shares here.
No, Acelyrin doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two primary order types:
Hit the Open button and your broker will execute the order.
If you want more info about investing in stocks on eToro, watch the how to video below:
Now that you own some SLRN stock, you'll want to stay up-to-date on your shares.
Start a watchlist to get notified of important updates regarding your SLRN stock.
To summarize, here are the 6 steps for buying Acelyrin stock:
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your investment in Acelyrin, add SLRN to your watchlist below.